Replies to post #99902 on Biotech Values

[acgood]

no kidding. it looks like they all wrote a selling plan that said, "i am going to dump half my shares the day after approval"??? that isn't what my mental definition of a 10b5-1 plan was.

[DewDiligence]

MNTA Insider Shareholdings

[Updated for SEC filings through 7/27/10. The table
entries include both ordinary and restricted shares
and both vested and non-vested options.]

 
                             Shares    Options 
 Officers 
 *Craig Wheeler (CEO)       470,469    675,000 
 *G Venkataraman‡ (SVP/R&D) 381,990    189,325 
 *Steven Brugger (COO)      255,075    246,194 
 *John Bishop (SVP/Pharma)   49,549    121,860 
 *Richard Shea (CFO)         40,471    249,200 
 *Bruce Leicher (Gen Cnsl)   38,734    137,050 
 *James Roach (CMO)          18,032    205,250 
  
 Directors 
 John Clarke                 77,123    126,000 
 †Bruce Downey                    0     45,000 
 Marsha Fanucci                   0    126,000 
 Peter Hutt                  67,863    201,500 
 *‡Ram Sasisekharan         306,344    126,000 
 *Bennett Shapiro             7,000    140,450 
 Elizabeth Stoner                 0     79,200 
 James Sulat (Chairman)           0     60,000 
 ======================   =========  ========= 
 All fifteen insiders     1,712,690  2,728,029 
  
 *10b5-1 selling plan in effect. 
 †Joined BoD 6/11/09. 
 ‡Co-founder.

[10nisman]

<< A fair amount of sales by MNTA insiders these last few days... Just got the Form 4s. >>

Fair amount of sales? A Co-founder and two VP's sold some shares under a Section 10b5-1 plan. Not a huge surprise nor a negative for the share price. They just took some chips off the table just like a number of people on this board have. Insiders still have the vast majority of their holdings.

10nis